FAS and brain neoplasm: One of these studies has been carried out and exposed in the US20100324116 patent, in which the inventors set out a siRNA-agent with the aim to reduce the amount of RNA encoding a CD95/CD95L gating polypeptides (e.g., FAPP2 or PATZ1 polypeptides) in significant quantities to sensitize brain tumor cells to CD95-mediated apoptosis [283, 284].